Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review53
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities46
Update on mGlu4 modulator patents: 2017 to present44
FAK inhibitors in cancer, a patent review – an update on progress36
Recent developments of agents targeting Vibrio cholerae : patents and literature data36
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature35
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)32
The role of patent analysis in target selection31
Mucormycosis medications: a patent review30
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)30
Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision30
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)29
Caspase inhibitors: a review on recently patented compounds (2016–2023)28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present27
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review25
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201324
An updated patent review of AKT inhibitors (2020 – present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
PDE1 inhibitors: a review of the recent patent literature (2008-present)21
A patent review of MAPK inhibitors (2018 – present)21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)21
0.049253940582275